The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-15 and is reviewed periodically as new material appears.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
== Mechanism == The hallmark feature of ferroptosis is the iron-dependent accumulation of oxidatively damaged phospholipids, i.e., lipid peroxides. The implication of Fenton chemistry via iron is crucial for the generation of reactive oxygen species and this feature can be exploited by sequestering iron in lysosomes. Reactive oxygen species (ROS) driving ferroptosis originate from three primary sources: the iron-dependent Fenton reaction, mitochondrial oxidative phosphorylation, and the NADPH oxidase (NOX) enzyme family. The NOX family, including NOX1, NOX2 (CYBB), and NOX4, transports electrons across the plasma membrane to produce superoxide and downstream ROS. The pentose phosphate pathway supplies NADPH, which serves as the essential electron donor for GPX4, FSP1/AIFM2, NOX, and POR — meaning that a higher intracellular NADPH ratio correlates with increased resistance to ferroptosis. The incorporation of polyunsaturated fatty acids (PUFAs) into membrane phospholipids is a prerequisite for ferroptosis. Two key enzymes govern this process: acyl-CoA synthetase long-chain family member 4 (ACSL4) activates PUFAs such as arachidonic acid and adrenic acid, and lysophosphatidylcholine acyltransferase 3 (LPCAT3) incorporates these activated PUFAs into the phospholipid bilayer. Monounsaturated fatty acids (MUFAs), including oleic acid and palmitoleic acid, compete with PUFAs for membrane incorporation and suppress ferroptosis due to their lower susceptibility to peroxidation.
5-HT2 receptors are G protein-coupled receptors that can regulate cellular signaling in the absence of a ligand. This can be explained by a two-state model (Figure 2) where the receptor is in equilibrium between two states, an active state (R*) and an inactive state (R). Basal effector activity is defined, in part, by the absolute level of (R*), which will increase along with increasing receptor density. Ligands that preferentially bind to and stabilize the R state are termed inverse agonists and reduce the effector activity. Agonists preferentially bind to and stabilize the R* state, thereby increasing effector activity. Neutral antagonists show equal affinity for both conformations and do not alter the equilibrium between the two states, however they occupy the receptor and can block the effect of both agonists and inverse agonists. 5-HT2C and 5-HT2A receptors have a similar amino acid sequence homology, with ~50% overall sequence identity and ~80% within the TM domains, resulting in a similar pharmacological profile for the two receptors. Both receptors couple the same cellular signal transduction pathways, PLC and PLA2, that lead to an accumulation of inositol phosphate and Ca2+ within the postsynaptic cell. The 5-HT2C receptors are the only G-protein coupled receptors known to undergo a post-transcriptional process of RNA editing. The 5-HT2C receptor gene is found on the X-chromosome, Xq24. This gene product undergoes an RNA editing process leading to a decrease in agonist binding affinity, however antagonist binding remains unaltered.
Days later, the Treasury released £12,300 for further development, and a small team of the RRS researchers were sworn to secrecy and began developing the concept. A system was to be built at the RRS station, and then moved to Orfordness for over-water testing. Wilkins would develop the receiver based on the GPO units, along with suitable antenna systems. This left the problem of developing a suitable pulsed transmitter. An engineer familiar with these concepts was needed.
Sources: en.wikipedia.org
R. Bruce Merrifield Award, American Peptide Society, 2015. Josef Rudinger Memorial Award (joint with Manfred Mutter), European Peptide Society, 2008. Burckhardt Helferich Prize for bioorganic chemistry, 2005. Vincent du Vigneaud Award, American Peptide Society, 2002. Max Planck Research Prize, Max Planck Society, 2001. Emil Fischer Medal, German Chemical Society, 1997.
In March 1997, the company patented this combination. The drug was approved in June 1997, by the FDA as Imodium Multi-Symptom Relief in the form of a chewable tablet. A caplet formulation was approved in November 2000. In November 1993, loperamide was launched as an orally disintegrating tablet based on Zydis technology. In 2013, loperamide was added to the WHO Model List of Essential Medicines.
This region is as extensive as the Amazon basin but has a very different climate as it lies farther south at a higher altitude. In the interior northeast, seasonal rainfall is even more extreme. South of Bahia, near the coasts, and more southerly most of the state of São Paulo, the distribution of rainfall changes, with rain falling throughout the year. The south enjoys subtropical conditions, with cool winters and average annual temperatures not exceeding 18 °C (64.4 °F); winter frosts and snowfall are not rare in the highest areas. The semiarid climatic region generally receives less than 800 millimeters (31.5 in) of rain, most of which generally falls in a period of three to five months of the year and occasionally less than this, creating long periods of drought. Brazil's 1877–78 Grande Seca (Great Drought), the worst in Brazil's history, caused approximately half a million deaths. A similarly devastating drought occurred in 1915. In 2024, for the first time, "a drought has covered all the way from the North to the country's Southeast". It is the strongest drought in Brazil since the beginning of measurement in the 1950s, covering almost 60% of the country's territory. The drought is linked to deforestation and climate change.
Double-blind trials have shown no difference in behavior between children given sugar-full or sugar-free diets, even in studies specifically looking at children with attention deficit hyperactivity disorder or those considered sensitive to sugar. A 2019 meta-analysis found no positive effect of sugar consumption on mood but did find an association with lower alertness and increased fatigue within an hour of consumption, known as a sugar crash. Sugar can, however, lead to a jump in blood sugar levels, and may make a child more active even if it does not cause clinical hyperactivity. Eating nuts, popcorn, or seeds does not increase the risk of diverticulitis. These foods may actually have a protective effect. Eating less than an hour before swimming does not significantly increase the risk of experiencing muscle cramps, and does not increase the risk of drowning. One study shows a correlation between alcohol consumption and drowning, but not between eating and stomach cramps. Vegan and vegetarian diets can provide enough protein for adequate nutrition. In fact, typical protein intakes of ovo-lacto vegetarians meet or exceed requirements. The American Dietetic Association maintains that appropriately planned vegetarian diets are healthful. However, a vegan diet does require dietary supplements. Swallowed chewing gum does not take seven years to digest. Chewing gum is mostly indigestible, and passes through the digestive system at the same rate as other matter.
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
Dry powder is commonly held at minus twenty degrees Celsius, desiccated and away from light. Cold storage slows degradation of the lyophilized material.